Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | MANBA | O00462 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL15069810 | 1.00 | LMNA (0.33) | LMNAGBA1CA1CA9MEN1 | |
| Ethylene Glycol SCHEMBL29359239 | 1.00 | LMNA (0.33) | LMNAGBA1CA1CA9MEN1 | |
| Alcohol SCHEMBL9222989 | 0.89 | LMNA (0.33) | LMNAGBA1CA1CA9MEN1 | |
| SCHEMBL15034 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL439067 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL44996 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8104271 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2860232 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15195848 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL732959 | 0.85 | CA1 (0.41) | CA1CA9MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401538-A1 | THERAPEUTIC MRNA VACCINE FOR MALIGNANCIES | ONCOCINE, LLC | 2022-12-22 | — | — | US | claimed |
| CN-112955513-A | Solvent-free marine antifouling paint and preparation method thereof | 厦门双瑞船舶涂料有限公司 | 2021-06-11 | — | — | CN | claimed |
| US-20210045414-A1 | PROCESS OF PRODUCING ALPHA-HYDROXY COMPOUNDS AND USES THEREOF | HALDOR TOPSØE A/S (DK) | 2021-02-18 | — | — | US | claimed |
| EP-3749635-A1 | PROCESS OF PRODUCING ALPHA-HYDROXY COMPOUNDS AND USES THEREOF | Haldor Topsøe A/S (DK) | 2020-12-16 | — | — | EP | claimed |
| CN-110511328-B | Branched-point-breaking type hyperbranched resin and preparation method and application thereof | 华南理工大学 | 2020-11-24 | — | — | CN | claimed |
| WO-2019154624-A1 | PROCESS OF PRODUCING ALPHA-HYDROXY COMPOUNDS AND USES THEREOF | HALDOR TOPSØE A/S (DK) | 2019-08-15 | — | — | WO | claimed |
| US-20180140662-A1 | Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-co-glycolide Polymers | NOVARTIS AG (CH) | 2018-05-24 | — | — | US | claimed |
| CN-104710576-B | Thermotropic crosslinking type shape memory polyurethane material and preparation method thereof | 四川大学 | 2017-04-19 | — | — | CN | claimed |
| CN-118291027-A | Environment-friendly ship antifouling paint suitable for long-term fresh water/fresh sea water outfitting, and preparation method and use method thereof | 厦门双瑞船舶涂料有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-117757236-A | Degradable material, preparation method and application | 杭州糖吉医疗科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11844837-B2 | Compositions of a polyorthoester and an organic acid excipient | HERON THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-3033113-B1 | A NOVEL PLGA-MODIFIED POLYETHYLENIMINE SELF-ASSEMBLY NANOTECHNOLOGY FOR NUCLEIC ACID AND DRUG DELIVERY | BAYLOR COLLEGE MEDICINE (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11613609-B2 | PLGA-modified polyethylenimine self-assembly nanotechnology for nucleic acid and drug delivery | BAYLOR COLLEGE OF MEDICINE (US) | 2023-03-28 | — | — | US | disclosed |
| US-20220401538-A1 | THERAPEUTIC MRNA VACCINE FOR MALIGNANCIES | ONCOCINE, LLC | 2022-12-22 | — | — | US | disclosed |
| WO-2002041844-A9 | CHEMOTHERAPEUTIC COMPOSITION USING NANOCRYSTALLINE CALCIUM PHOSPHATE PASTE | ETEX CORP (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002065981-A2 | CHEMOTHERAPEUTIC COMPOSITION USING CALCIUM PHOSPHATE PASTE | ETEX CORPORATION (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002041844-A2 | CHEMOTHERAPEUTIC COMPOSITION USING NANOCRYSTALLINE CALCIUM PHOSPHATE PASTE | ETEX CORPORATION (US) | 2002-05-30 | — | — | WO | disclosed |
| US-5277900-A | Applying a wax of hydroxycarboxylic acid | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1994-01-11 | — | — | US | disclosed |
| US-4155992-A | SUSTAINED RELEASE | ALZA CORPORATION (US) | 1979-05-22 | — | — | US | disclosed |
| US-4070347-A | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality | ALZA CORPORATION (US) | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844837-B2 | Compositions of a polyorthoester and an organic acid excipient | OTC, OAT, SLCO2A1 | LMNA 3136/4885GBA1 1245/4885CA1 831/4885 |
| US-20210045414-A1 | PROCESS OF PRODUCING ALPHA-HYDROXY COMPOUNDS AND USES THEREOF | HAAO, CYP8B1, PAH | LMNA 2819/4885GBA1 2350/4885CA1 4182/4885 |
| US-20180140662-A1 | Sustained Release Formulation Comprising Octreotide and Two or More Polylactide-co-glycolide Polymers | SSTR2, SSTR4, SSTR3 | LMNA 3501/4885GBA1 772/4885CA1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.